Columbia University

Technology Ventures

Bristol Myers Squibb II-ON RFP: Immuno-Oncology and Cell Therapy

Deadline: 
Friday, February 5, 2021 - 5:00pm

Bristol Myers Squibb seeks proposals on topics designed to address questions developed by its Immuno-Oncology and Cell Therapy (IOCT) Thematic Research Center.

Areas of interest:

  • Approaches to normalize the tumor vasculature to improve cell therapy/T cell engagers/NK cell engager therapies
  • Novel technology which can support cell therapy target identification for solid tumors
  • Targeting T cell metabolism pathways to improve T cell fitness for cell therapy in vivo

RFP guidelines:

  • Total budgets (direct + indirect) generally should not exceed USD $250k-350k/ 12 month funding period
  • Please utilize II-ON Proposal Template for your submission (see Related Documents)
  • Collaborating with multiple institutions encouraged

Timeline for submission: 

  • Proposals due February 5, 2021 to techventures@columbia.edu
  • BMS Review process February 12 – March 5, 2021
  • Communication of decisions week of March 12, 2021